期刊文献+

干扰素α2a对人结肠癌细胞胸苷磷酸化酶表达和5'脱氧氟尿苷抗癌活性的影响 被引量:9

Influence of interferon-α2a on thymidine phosphorylase expression and anticancer activity of 5'-deoxy-fluorouridine in human colon carcinoma cell lines LOVO and SW480
原文传递
导出
摘要 目的探讨干扰素-α2a(IFN-αt2a)对人结肠癌细胞胸苷磷酸化酶(TP)mRNA表达水平以及5'-脱氧氟尿苷(5’-DFUR)和氟尿嘧啶(5-FU)抗癌效应的影响。方法不同剂量IFN-α2a分别处理人结肠癌细胞LOVO和SW480.荧光定量PCR检测TPmRNA表达水平:MTT法检测联合应用IFN-α2a前后5.FU和5'-DFUR对LOVO和SW480抑制作用的半数有效浓度(IC50)变化情况。结果与0U/mlIFN-α2a浓度组相比.500U/ml及5000U/ml组可明显上调LOVO和SW480细胞TPmRNA表达(P〈0.01),而50U/ml则对上述两种细胞TPmRNA表达水平无明显影响(P〉0.05)。联合应用浓度为20U/ml的IFN-α2a后.5.FU对LOVO和SW480细胞的IC50无明显改变(P〉0.05).但5’-DFUR的IC50则明显降低(P〈0.05)。结论IFN-α2a能上调结肠癌细胞TPmRNA的表汰水平并可使5'-DFIIR对结肠痛细胞的1C50明显下降而对5-FI7则无明显影响。 Objective To detect the effect of interferon-α2a (IFN-α2a) on thymidine phosphorylase (TP) mRNA expression levels and the anticancer activity of 5-fluorouracil (5-FU) and 5'- deoxy-fluorouridine(5'-DFUR) in human colon carcinoma cell lines LOVO and SW480. Methods Two human colon cancer cell lines LOVO and SW480 were cultured and treated with IFN-α2a at a series of dosage, and fluorescence quantitative PCR was carried out to detect the TP mRNA expression levels in these 2 cell lines. Then MTY assay and software Templet were used to determine the change of 50% inhibition concentration of 5-FU or 5'-DFUR combined with IFN-α2a on the two cell lines. Results The TP mRNA expressions were up-regulated significantly by IFN-α2a at the doses of 500 U/ml and 5000 U/ml in LOVO(P〈0.01). Compared with untreated cells(IFN-α2a 0 U/ml), no significance was found for TP mRNA expression levels in LOVO and SW480 treated by IFN-α2a at the dose of 50 U/ml (P〉0.05). There was no significant difference for TP mRNA expression in SW480 between the dose of 0 U/ml and 500 U/ml of IFN-α2a (P〉0.05), while a significant increace was detected at the dose of 5000 U/ml (P〈0.O1). No significant difference was found for the IC50 values after treatment of 5-FU combined with IFN-α2a (20 U/ml) on LOVO and SW480 compared with 5-FU alone, while the ICSO values after treatment of 5'-DFUR combined with IFN-α2a decreased significantly compared with 5'- DFUR alone (P〈0.05). Conclusion There is no direct inhibition effect of IFN-α2a on LOVO and SW480 in vitro, while it can up-regulate TP mRNA expression levels both in LOVO and SW480, and enhance the antieancer effect of 5'-DFUR on these 2 cell lines.
出处 《中华胃肠外科杂志》 CAS 2012年第7期719-722,共4页 Chinese Journal of Gastrointestinal Surgery
基金 国家自然科学基金,广东省自然科学基金
关键词 结肠肿瘤 胸苷磷酸化酶 干扰素-Α2A 氟尿嘧啶 5’-脱氧氟尿苷 Colonic neoplasms Thymidine phosphorylase Interferon-α2a Fluorouracil 5'-deoxy-5-fluorouridine
  • 相关文献

参考文献12

  • 1Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet- derived endothelial cell growth factor. Nature, 1989,338 (6216) :557-562.
  • 2Ueda M, Terai Y, Kumagai K, et al. Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells. Int J Cancer, 2001,91 (6):778-782.
  • 3Yao Y, Kubota T, Sato K, et al. Interferons upregulate thymidine phosphorylase expression via JAK-STAT-dependent transcriptional activation and mRNA stabilization in human glioblastoma cells. J Neurooncol, 2005,72(3):217-223.
  • 4de Bruin M, Smid K, van der Ent MA, et al. Upregulation of platelet derived endothelial cell growth factor/thymidine phosphorylase by interferon alpha. Nucleosides Nucleotides Nucleic Acids, 2004,23 ( 8-9 ) : 1367-1370.
  • 5Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chem Parm, 1993,32(5) :333-338.
  • 6Morita T, Matsuzaki A, Tokue A. Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. lnt J Cancer, 2001,92 (3): 451-456.
  • 7Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase 11 trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002,86 (9): 1367-1372.
  • 8Twelves C. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase m trials. Eur .1 Caneer, 2002,38(Suppl 2) : 15-20.
  • 9张继民,刘明姬,沟井贤幸,椎叶健一,佐々木严,松野正纪.结直肠癌组织中巨噬细胞表达胸苷磷酸化酶并与血管新生相关[J].中华胃肠外科杂志,2003,6(4):247-250. 被引量:19
  • 10游伟,张继民,邹湘才,郝卓芳,廖德贵,黄世章,洪楚原.结直肠癌肝转移组织中胸苷磷酸化酶表达[J].国际外科学杂志,2009,36(7):440-444. 被引量:13

二级参考文献17

  • 1张继民,刘明姬,溝井賢幸,椎葉健一,佐佐木巌,松野正纪.单核-巨噬细胞表达的胸苷磷酸化酶增强去氧氟尿苷抗结肠癌细胞活性[J].中华医学杂志,2004,84(9):718-724. 被引量:14
  • 2游伟,张继民,邹湘才.结直肠癌组织中胸苷磷酸化酶表达与5’-脱氧氟尿苷靶向治疗的关系[J].国际外科学杂志,2006,33(4):287-291. 被引量:3
  • 3邹湘才,张继民,游伟.结直肠癌组织中巨噬细胞因子的分子生物学作用[J].国际外科学杂志,2007,34(5):308-313. 被引量:2
  • 4Maeda K, Kang SM, Ogawa M, et al. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma, Int J Cancer,1997,74: 545-550.
  • 5Toi M, Ueno T, Matsumoto H, et al. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer.Clin Cancer Ras, 1999, 5: 1131-1137.
  • 6Takcbayashi Y, Akiyama S, Akiba S, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylasc, in human colorectal carcinoma. J Nat Cancer Inst,1996, 88:1110-1117.
  • 7Amaya H, Tanigawa N, Lu C, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis,survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett, 1997, 119: 227-235.
  • 8Matsumura M, Chiba Y, Lu C, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression correlated with tumor angiogenesis and macrophage infiltration in colorectal cancer. Cancer Lett, 1998, 128: 55-63.
  • 9Haba A, Monden T, Sekimoto M, et al. PyNPase expression in human colon cancer. Cancer Lett, 1998, 122: 85-92.
  • 10Nishida M, Hino A, Mori K, et al. Preparation of anti-human thymidine phosphorylase monoelonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull, 1996, 19:1407-1411.

共引文献21

同被引文献50

引证文献9

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部